El-Domyati M, El-Din W H, Rezk A F, Chervoneva I, Lee J B, Farber M, Uitto J, Igoucheva O, Alexeev Vitali
Department of Dermatology, STDs and Andrology At Minia University, Minia, Egypt.
Department of Dermatology and Cutaneous Biology, Sidney Kimmel Medical College, Thomas Jefferson University, 233 S. 10th Street, BLSB, Suite 430, Philadelphia, PA, 19107, USA.
Arch Dermatol Res. 2022 Apr;314(3):275-284. doi: 10.1007/s00403-021-02228-9. Epub 2021 Apr 17.
Vitiligo is an acquired pigmentary skin disorder that currently lacks standardized treatment and validated biomarkers to objectively evaluate disease state or therapeutic response. Although prior studies have linked vitiligo autoimmunity with CXCL10/CXCL9-mediated recruitment of leukocytes to the skin, only limited clinical data are available regarding CXCL10 as vitiligo biomarker. To evaluate the utility of systemic CXCL10 as a predictor of disease progression and treatment response on a large cohort of vitiligo patients. CXCL10 levels in lesional, perilesional, and unaffected skin of vitiligo patient (n = 30) and in the serum (n = 51) were measured by quantitative ELISA. CXCL10 expression, recruitment of leukocytes, and inflammatory infiltrates were evaluated by histochemical (n = 32) and immunofluorescence (n = 10) staining. Rigorous cross-sectional and longitudinal biostatistical analysis were employed to correlate CXCL10 levels with disease variables, treatment response, and outcome. We demonstrated that elevated CXCL10 level (2 pg/mm and higher) in lesional skin correlates with increased leukocytic infiltrate, disease duration (< 2 year), and its higher level in the serum (50 pg/ml and higher). Changes in CXCL10 serum levels in patients treated with psoralen plus UVA (PUVA) phototherapy, narrowband UVB (NB-UVB) phototherapy, and systemic steroids (SS) correlated with changes in the intralesional CXCL10 levels in repigmented skin. NB-UVB and SS regimens provided most consistent CXCL10 mean change, suggesting that these regimens are most effective in harnessing CXCR3-mediated inflammatory response. Serum CXCL10 is a useful vitiligo biomarker, which predicts lesional skin leukocytic infiltration, and vitiligo treatment response and outcome.
白癜风是一种后天性色素性皮肤病，目前缺乏标准化治疗方法和经过验证的生物标志物来客观评估疾病状态或治疗反应。尽管先前的研究已将白癜风自身免疫与CXCL10/CXCL9介导的白细胞向皮肤的募集联系起来，但关于CXCL10作为白癜风生物标志物的临床数据有限。为了评估全身性CXCL10作为大量白癜风患者疾病进展和治疗反应预测指标的效用。通过定量ELISA测量了30例白癜风患者皮损、皮损周围和未受累皮肤以及51例患者血清中的CXCL10水平。通过组织化学（32例）和免疫荧光（10例）染色评估CXCL10表达、白细胞募集和炎症浸润。采用严格的横断面和纵向生物统计学分析来关联CXCL10水平与疾病变量、治疗反应和结果。我们证明，皮损皮肤中CXCL10水平升高（2 pg/mm及以上）与白细胞浸润增加、病程（<2年）及其血清中较高水平（50 pg/ml及以上）相关。接受补骨脂素加紫外线A（PUVA）光疗、窄带紫外线B（NB-UVB）光疗和全身性类固醇（SS）治疗的患者血清CXCL10水平的变化与色素再生皮肤中皮损内CXCL10水平的变化相关。NB-UVB和SS方案提供了最一致的CXCL10平均变化，表明这些方案在利用CXCR3介导的炎症反应方面最有效。血清CXCL10是一种有用的白癜风生物标志物，可预测皮损皮肤白细胞浸润以及白癜风治疗反应和结果。
